Between rapidly shifting tariffs, freezes to federal grant funding and changing U.S. Food and Drug Administration policies, R.I. Bio Director Glenn Robertelli acknowledges that 2025 was a turbulent year for the life sciences. But at the local level, Robertelli says, the sector has managed to ride out the storm. “Here in Rhode Island, despite the
Already a Subscriber? Log in
To Continue Reading This Article
Become a Providence Business News subscriber and get immediate access to all of our premier content and much more.Learn More and Become a Subscriber
